POXEL SA FRANCE Operating Income 2019-2020 | PXXLF

POXEL SA FRANCE operating income from 2019 to 2020. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
POXEL SA FRANCE Annual Operating Income
(Millions of US $)
2020 $-34
2019 $-28
2018 $15
POXEL SA FRANCE Quarterly Operating Income
(Millions of US $)
2020-12-31
2020-06-30
2019-12-31
2018-12-31 $88
2018-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.161B $0.008B
Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company's product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29